Leora Horwitz, MD, MHS
About
Biography
Leora Horwitz, MD is a general internist who studied social science as an undergraduate and is now a clinician researcher focused on quality and safety in healthcare. In particular, she focuses on systems and practices intended to bridge gaps or discontinuities in care. She has studied shift-to-shift transfers among physicians and among nurses, transfers from the emergency department to inpatient units, and the transition from the hospital to home. She is currently adjunct faculty at Yale; her primary work is at NYU Langone Health, where she directs the Center for Healthcare Innovation and Delivery Science and the division of healthcare delivery science in the Department of Population Health. Her current work is focused primarily on developing a learning health system through innovations in clinical delivery and in data capture and analysis.
Appointments
Departments & Organizations
- Internal Medicine
- Yale Ventures
- Yale-New Haven Hospital Primary Care Center
Education & Training
- Fellow
- Yale University School of Medicine (2007)
- MHS
- Yale School of Medicine (2006)
- Chief Resident
- Mount Sinai Hospital (2004)
- Resident
- Mount Sinai Hospital (2003)
- MD
- Harvard Medical School (2000)
- BA
- Harvard University (1996)
Research
Overview
Medical Subject Headings (MeSH)
ORCID
0000-0003-1800-6040
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Jeph Herrin, PhD
Huihui Yu, PhD
Jacqueline Grady, MS
Arjun Venkatesh, MD, MBA, MHS
Faseeha Altaf, MPH, BS
Harlan Krumholz, MD, SM
Quality of Health Care
Publications
2024
Differentiation of Prior SARS-CoV-2 Infection and Postacute Sequelae by Standard Clinical Laboratory Measurements in the RECOVER Cohort.
Erlandson K, Geng L, Selvaggi C, Thaweethai T, Chen P, Erdmann N, Goldman J, Henrich T, Hornig M, Karlson E, Katz S, Kim C, Cribbs S, Laiyemo A, Letts R, Lin J, Marathe J, Parthasarathy S, Patterson T, Taylor B, Duffy E, Haack M, Julg B, Maranga G, Hernandez C, Singer N, Han J, Pemu P, Brim H, Ashktorab H, Charney A, Wisnivesky J, Lin J, Chu H, Go M, Singh U, Levitan E, Goepfert P, Nikolich J, Hsu H, Peluso M, Kelly J, Okumura M, Flaherman V, Quigley J, Krishnan J, Scholand M, Hess R, Metz T, Costantine M, Rouse D, Taylor B, Goldberg M, Marshall G, Wood J, Warren D, Horwitz L, Foulkes A, McComsey G. Differentiation of Prior SARS-CoV-2 Infection and Postacute Sequelae by Standard Clinical Laboratory Measurements in the RECOVER Cohort. Annals Of Internal Medicine 2024 PMID: 39133923, DOI: 10.7326/m24-0737.Peer-Reviewed Original ResearchCitationsAltmetricConceptsPostacute sequelae of SARS-CoV-2 infectionSARS-CoV-2 infectionLaboratory markersSARS-CoV-2Laboratory valuesUrinary albumin-creatinine ratioClinical laboratory markersStandard clinical laboratory testsAlbumin-creatinine ratioClinical laboratory valuesHemoglobin A<sub>1c</sub> (HbA<sub>1c</sub>Clinically useful biomarkersClinical laboratory testsClinical laboratory measurementsPropensity score adjustmentSequelae of SARS-CoV-2 infectionPreexisting diabetesIndex dateMeasured 6 monthsClinical significanceNational Institutes of HealthStudy visitsEnrollment siteRisk factorsClinical biomarkersPrescription Patterns for Sodium-Glucose Cotransporter 2 Inhibitors in U.S. Health Systems
Shin J, Xu Y, Chang A, Carrero J, Flaherty C, Mukhopadhyay A, Inker L, Blecker S, Horwitz L, Grams M. Prescription Patterns for Sodium-Glucose Cotransporter 2 Inhibitors in U.S. Health Systems. Journal Of The American College Of Cardiology 2024, 84: 683-693. PMID: 39142721, DOI: 10.1016/j.jacc.2024.05.057.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsSodium-glucose cotransporter 2Class 1A recommendationSodium-glucose cotransporter 2 inhibitor therapyChronic kidney diseaseU.S. health systemHealth systemInhibitor prescriptionHeart failurePrescription ratesInhibitor therapyInhibitor useSodium-glucose cotransporter 2 inhibitorsSodium-glucose cotransporter 2 inhibitor useOptum Labs Data WarehouseProportion of patientsSGLT2 inhibitor usePresence of diabetesRecurrent cardiovascular eventsAtherosclerotic cardiovascular diseaseCotransporter 2Analysis of U.S. dataSevere albuminuriaPrescription patternsCardiovascular eventsCommercial insurancePost–Acute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) After Infection During Pregnancy
Metz T, Reeder H, Clifton R, Flaherman V, Aragon L, Baucom L, Beamon C, Braverman A, Brown J, Cao T, Chang A, Costantine M, Dionne J, Gibson K, Gross R, Guerreros E, Habli M, Hadlock J, Han J, Hess R, Hillier L, Hoffman M, Hoffman M, Hughes B, Jia X, Kale M, Katz S, Laleau V, Mallett G, Mehari A, Mendez-Figueroa H, McComsey G, Monteiro J, Monzon V, Okumura M, Pant D, Pacheco L, Palatnik A, Palomares K, Parry S, Pettker C, Plunkett B, Poppas A, Ramsey P, Reddy U, Rouse D, Saade G, Sandoval G, Sciurba F, Simhan H, Skupski D, Sowles A, Thorp J, Tita A, Wiegand S, Weiner S, Yee L, Horwitz L, Foulkes A, Jacoby V. Post–Acute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) After Infection During Pregnancy. Obstetrics And Gynecology 2024, 144: 411-420. PMID: 38991216, PMCID: PMC11326967, DOI: 10.1097/aog.0000000000005670.Peer-Reviewed Original ResearchAltmetricConceptsSARS-CoV-2 infectionSARS-CoV-2Clinical characteristicsSevere acute respiratory syndrome coronavirus 2Gastrointestinal symptomsAcute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Risk factorsPost-acute sequelae of severe acute respiratory syndrome coronavirus 2Syndrome coronavirus 2Acute SARS-CoV-2 infectionHistory of obesityMulticenter cohort studyAssociated with increased prevalenceMultivariate logistic regression modelPostexertional malaiseCoronavirus 2Median timeAcute infection severityLogistic regression modelsAcute infectionCohort studyPredominant symptomPrimary outcomeStudy visitsAnalysis of Clinical Criteria for Discharge Among Patients Hospitalized for COVID-19: Development and Validation of a Risk Prediction Model
Schnipper J, Oreper S, Hubbard C, Kurbegov D, Egloff S, Najafi N, Valdes G, Siddiqui Z, O.’Leary K, Horwitz L, Lee T, Auerbach A. Analysis of Clinical Criteria for Discharge Among Patients Hospitalized for COVID-19: Development and Validation of a Risk Prediction Model. Journal Of General Internal Medicine 2024, 1-13. PMID: 38937368, DOI: 10.1007/s11606-024-08856-x.Peer-Reviewed Original ResearchConceptsTime of dischargeInternal validation setPost-discharge readmissionRisk factorsDays of dischargeRetrospective observational cohort studyIndependent risk factorReceiver operating characteristic curveObservational cohort studyReversible risk factorsAssociated with lower oddsPatients 7Lack of improvementRetrospective studyValidation setFollow-upCohort studyRisk prediction modelReadmission risk scoreAcademic centersPositive testPatientsRisk scoreCOVID-19 respiratory diseaseLower oddsMeasuring Equity in Readmission as a Distinct Assessment of Hospital Performance
Nash K, Weerahandi H, Yu H, Venkatesh A, Holaday L, Herrin J, Lin Z, Horwitz L, Ross J, Bernheim S. Measuring Equity in Readmission as a Distinct Assessment of Hospital Performance. JAMA 2024, 331: 111-123. PMID: 38193960, PMCID: PMC10777266, DOI: 10.1001/jama.2023.24874.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsBlack patientsPatient populationHospital characteristicsHospital-wide readmission measureDual-eligible patientsHospital patient populationCross-sectional studyMeasures of hospitalHealth care qualityPatient demographicsReadmission ratesClinical outcomesPatient raceEligible hospitalsReadmissionMAIN OUTCOMEReadmission measuresMedicare dataUS hospitalsHospitalCare qualityPatientsMedicaid ServicesOutcomesLower percentageLB01 Development of post-acute sequelae of SARS-CoV-2 (PASC) after infection in pregnancy: NIH RECOVER-Pregnancy Cohort
Metz T, Reeder H, Clifton R, Flaherman V, Aragon L, Baucom L, Braverman A, Cao T, Dionne J, Foulkes A, Gross R, Han J, Hess R, Horwitz L, Jia X, Kale M, Mehari A, Monteiro J, Pant D, Ramsey P, Jacoby V. LB01 Development of post-acute sequelae of SARS-CoV-2 (PASC) after infection in pregnancy: NIH RECOVER-Pregnancy Cohort. American Journal Of Obstetrics And Gynecology 2024, 230: s6. DOI: 10.1016/j.ajog.2023.11.1258.Peer-Reviewed Original ResearchAltmetric
2023
Researching COVID to enhance recovery (RECOVER) pregnancy study: Rationale, objectives and design
Metz T, Clifton R, Gallagher R, Gross R, Horwitz L, Jacoby V, Martin-Herz S, Peralta-Carcelen M, Reeder H, Beamon C, Chan J, Chang A, Costantine M, Fitzgerald M, Foulkes A, Gibson K, Güthe N, Habli M, Hackney D, Hoffman M, Hoffman M, Hughes B, Katz S, Laleau V, Mallett G, Mendez-Figueroa H, Monzon V, Palatnik A, Palomares K, Parry S, Pettker C, Plunkett B, Poppas A, Reddy U, Rouse D, Saade G, Sandoval G, Schlater S, Sciurba F, Simhan H, Skupski D, Sowles A, Thaweethai T, Thomas G, Thorp J, Tita A, Weiner S, Weigand S, Yee L, Flaherman V, Initiative O. Researching COVID to enhance recovery (RECOVER) pregnancy study: Rationale, objectives and design. PLOS ONE 2023, 18: e0285351. PMID: 38128008, PMCID: PMC10734909, DOI: 10.1371/journal.pone.0285351.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsSARS-CoV-2 infectionSARS-CoV-2Long-term outcomesMonths of agePregnancy cohortMaternal-Fetal Medicine Units NetworkHealth outcomesSARS-CoV-2 antibody testingAdverse long-term outcomesEunice Kennedy Shriver National InstitutePost-acute sequelaeLong-term sequelaeClinical trial registrationMaternal-child dyadsNational InstituteMulti-site observational studyCalifornia San FranciscoUnique physiologic changesPregnancy modifiesMaternal infectionMultiple gestationsOverall cohortRetrospective cohortAntibody testingLong COVID3 A/B testing in healthcare: how you can apply tech industry methods to improve quality in your system
Krelle H, King W, Jones S, Rosen K, Tsuruo S, Klapheke N, Stadelman J, Horwitz L. 3 A/B testing in healthcare: how you can apply tech industry methods to improve quality in your system. 2023, a1.3-a1. DOI: 10.1136/bmjoq-2023-ihi.3.Peer-Reviewed Original ResearchImpact of Visit Volume on the Effectiveness of Electronic Tools to Improve Heart Failure Care
Mukhopadhyay A, Reynolds H, King W, Phillips L, Nagler A, Szerencsy A, Saxena A, Klapheke N, Katz S, Horwitz L, Blecker S. Impact of Visit Volume on the Effectiveness of Electronic Tools to Improve Heart Failure Care. JACC Heart Failure 2023, 12: 665-674. PMID: 38043045, DOI: 10.1016/j.jchf.2023.11.002.Peer-Reviewed Original ResearchCitationsAltmetricConceptsMineralocorticoid antagonistsVolume groupVisit volumeElectronic health record toolsPhysician workloadGuideline-recommended therapiesReduced ejection fractionUsual care armHeart failure carePrespecified subgroup analysisHigh-volume groupCluster-randomized trialLog-binomial modelsBusy practice settingsCare armEHR alertUsual careEjection fractionHeart failureSubgroup analysisEHR toolsNumber of visitsCardiology officePractice settingsStudy period
2020
Trends in COVID‐19 Risk‐Adjusted Mortality Rates
Horwitz LI, Jones SA, Cerfolio RJ, Francois F, Greco J, Rudy B, Petrilli CM. Trends in COVID‐19 Risk‐Adjusted Mortality Rates. Journal Of Hospital Medicine 2020, 16: 90-92. PMID: 33147129, DOI: 10.12788/jhm.3552.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsHospital mortalityMortality rateHealth systemRisk-adjusted mortality ratesAdmission vital signsStandardized mortality ratioCoronavirus disease 2019Academic health systemPatient characteristicsClinical factorsMortality ratioDisease 2019High mortalityVital signsMortalityComorbiditiesCOVID-19Laboratory resultsEarlier reportsHospitalizationPatientsHospiceDemographics
Links & Media
News
- July 18, 2017
Study: Reducing hospital readmissions does not increase mortality rates
- January 04, 2017
When it comes to reducing hospital readmissions, financial penalties work
- April 11, 2016
Program reduces hospital readmissions rate
- February 05, 2015
After hospital discharge, deadly heart risks can remain for up to a year
Related Links
Get In Touch
Contacts
Locations
Section of General Internal Medicine
Academic Office
E.S. Harkness Memorial Hall, Building A
367 Cedar Street, Ste Suite 401
New Haven, CT 06510